Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--(BUSINESS WIRE)-- Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.

• Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T.
• Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240829770488/en/

Matthew DeYoung
Investor Relations and Media
Argot Partners
[email protected]

Source: Abcuro, Inc.

You May Also Be Interested In

• Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize
• Calvin Klein Collection by Veronica Leoni Spring 2027 Runway Show Presented in New York City
• Ethereum Price Prediction: ETH Could Jump 24% to $3,050 as AlphaPepe Gives Retail a 34x Path to $1